Description
Technical Information & Resources
Frequently Asked Questions
How should TrailBio® XAV939 stock solutions be prepared?
TrailBio® XAV939 is soluble in DMSO at 15.62 mg/ml, approximately 50 mM, with ultrasonic treatment and warming. For cell culture workflows, prepare concentrated DMSO stocks and dilute into culture media immediately before use. When preparing working solutions, ensure the final DMSO concentration in culture media remains below 0.5% (v/v) to prevent cellular toxicity.
What concentration of TrailBio® XAV939 should I use?
TrailBio® XAV939 demonstrates potent tankyrase inhibition, with reported IC₅₀ values of 2 nM for TNKS2 and 5 nM for TNKS1. Activity against ARTD2 and ARTD1 is reported at higher IC₅₀ values of 479 nM and 5.5 µM, respectively. For cell culture workflows, working concentration should be optimized by cell type and protocol.
How does TrailBio® XAV939 inhibit Wnt signaling?
TrailBio® XAV939 inhibits tankyrase (TNKS1 and TNKS2) activity, which helps stabilize AXIN and supports β-catenin degradation. This reduces downstream Wnt pathway activation and can be used to study pathways regulated by Wnt signaling.
What research applications is TrailBio® XAV939 commonly used for?
TrailBio® XAV939 is applicable to Wnt signaling inhibition workflows, including hiPSC studies, osteoblast induction, neuronal differentiation, cardiomyocyte differentiation, and cancer signaling research models.
Supporting Publications
- Foundational paper identifying XAV939 as a Wnt/β-catenin inhibitor that stabilizes AXIN through TNKS1/TNKS2 inhibition.
Hwnag et al. (2017). Journal of Cellular Physiology
- Human iPSC citation showing cardiomyocyte differentiation with XAV939/Wnt modulation and reported cardiomyocyte enrichment.
Stakheev et al. (2019). Scientific Reports
- Study showing XAV939 inhibits β-catenin nuclear translocation and enhances lymphocyte-mediated elimination of prostate cancer cells in vitro.
